THE BELGIAN OPHTHALMIC ASSOCIATIONS
View abstract
This abstract is assigned to session AOB Free papers
| Title | A retrospective data collection study in patients receiving two or more OZURDEX® injections for macular edema secondary to retinal vein occlusion (RVO) |
| Purpose | This retrospective observational study was designed to investigate the re-injection interval, efficacy and safety of OZURDEX® in routine clinical practice in the Belgian RVO population. |
| Methods | This analysis contains data from 26 patients from 7 sites in Belgium who had received at least 2 OZURDEX® injections. Data was collected from the time of the first injection until 6 months following the latest OZURDEX® injection in each patient. Analysis was performed for the full analysis set, i.e. 26 patients with RVO, and for the sub-population with central retinal vein occlusion (CRVO, n=23). |
| Results | The mean time to OZURDEX® re-injection between 1st and 2nd treatments was 144 days (5.14 months). In the overall population, a mean LogMAR BCVA improvement compared to baseline from 0.65 to 0.52 was recorded 7-12 weeks following the last OZURDEX® injection. For CRVO, the mean improvement was from 0.67 to 0.52. Following the 1st injection, 50% of patients showed an improvement of ≥2 lines compared to baseline. 42% showed an improvement of ≥3 lines. Following the 2nd injection, 2 and 3 line improvements compared to baseline were shown by 38% and 35% of patients respectively. Reductions in central retinal thickness were also observed. Intraocular pressure measurements over 25mmHg were reported in 5 patients (19%). No glaucoma surgeries were reported. 4 patients underwent cataract surgery during the course of the study, all of whom presented with lens opacity prior to receiving OZURDEX®. |
| Conclusion | In this observational study, OZURDEX® was found to be safe and effective with repeat treatments. The mean re-injection interval for RVO patients was 5.14 months. |
Authors 1
| Last name | VAN CALSTER |
| Initials | J |
| Department | University Hospitals Leuven |
| City | Leuven |
Authors 2
| Last name | On behalf of the Belgian Ozurdex Medical Need Program Investigators |